Ramoplanin, a potent cyclic lipoglycodepsipeptide antibiotic, has been reported to be active against aerobic and anaerobic gram-positive bacteria. Mechanistic studies show that Ramoplanin prevents cell wall peptidoglygan formation and further enzymatic processing via binding to lipid II, a key intermediate moeity. Ramoplanin has also displayed a low affinity for Lipid I, a substrate for the MurG step of cell wall formation.
